Clinical trials: Dupilumab
Prostate Cancer
Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
This is a single-center, single arm, open-label phase II study evaluating the safety, anti-tumor effect, and immunogenicity of neoadjuvant Dupixent given prior to radical prostatectomy.
- Trial name
- NCT03886493
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Food Allergy
Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Previously Treated With Linvoseltamab
This is an expanded access program of dupilumab. The objective of the program is to provide continued dupilumab to adult participants with severe IgE-mediated food allergy who were previously treated with a short course of…
- Trial name
- NCT06631677
- Testing
- Dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Study in Male and Female Adult Patients With Atopic Dermatitis Treated With Dupilumab in Taiwan
Primary objective: To characterize the use patterns of phototherapy and immunosuppressants prior to dupilumab treatment for adult AD patients, who are eligible for dupilumab reimbursement in Taiwan (e.g., used regimens, reason…
- Trial name
- NCT05442645
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sanofi
COPD (Chronic Obstructive Pulmonary Disease), COPD
Dupilumab in Type 2-Inflamed COPD Across the Full Spectrum of Airflow Limitation: An Italian Multicentre Retrospective Cohort Study
This multicentre retrospective cohort study describes lung function and patient-reported outcomes in adults with chronic obstructive pulmonary disease (COPD) and type 2 inflammation who received add-on dupilumab in routine…
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), COPD, Eosinophilia
- Trial name
- DUPICENTRO (NCT07788092)
- Testing
- Dupilumab
- Where
- 6 sites in Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Ospedaliera di Perugia
Atopic Dermatitis
BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Dermatitis
The BioDay Registry aims to address the need for daily practice data regarding the effectiveness and safety of new systemic treatment options (like biologics and Janus kinase inhibitors) in patients with atopic dermatitis and…
- Trial name
- BioDay (NCT03549416)
- Where
- 14 sites in Netherlands
- Volunteers
- 1,200 people
- Sponsor
- UMC Utrecht
Asthma
Viral Infection in Asthma (VIA) Study
Often when people with asthma get a virus caused by the common cold (rhinovirus), they also experience an increase or worsening of their asthma symptoms.
- Trial name
- VIA (NCT04380038)
- Testing
- Dupilumab Injectable Product
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Virginia
Dermatitis, Atopic
Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy
The Spanish Registry of Systemic therapy in atopic eczema, BIOBADATOP, assesses drug safety and treatment effectiveness as well as treatment impact on quality of life in children and adults with atopic eczema receiving systemic…
- Trial name
- BIOBADATOP (NCT05674695)
- Testing
- Ciclosporin
- Where
- 9 sites in Spain
- Volunteers
- 2,500 people
- Sponsor
- Fundación Academia Española de Dermatología
Atopic Dermatitis, Atopic Dermatitis Eczema
The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients
This is a single-arm, open-label study, which will examine the effect of dupilumab on quality of life in atopic dermatitis patients.
- Trial name
- NCT03667014
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of California, San Francisco
Atopic Dermatitis
An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing Dupilumab
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- CAN UpTIMISE (NCT05394792)
- Where
- 25 sites in Canada
- Volunteers
- 111 people
- Sponsor
- AbbVie
Atopic Dermatitis
Microbiome in Atopic Dermatitis Under Systemic Therapy
The skin microbiome plays a role in the pathogenesis of atopic dermatitis. However, it is unclear whether the range of microbiota on the skin is the cause or consequence of atopic skin inflammation.
- Trial name
- BIO-AD (NCT05099315)
- Testing
- not applicable, observational study
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- Charite University, Berlin, Germany
Asthma
Phenotypic and Functional Characterization of Neutrophils and Eosinophils in Severe Asthma Treated With Biotherapy
Neutrophils and eosinophils can have different functions. Depending on their environment, they can be more or less active, with more or less inflammatory activity.
- Trial name
- CaPHe (NCT05972213)
- Where
- France
- Volunteers
- 105 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.
- Trial name
- ADapt (NCT05369403)
- Testing
- Lebrikizumab
- Where
- 37 sites in United States
- Volunteers
- 86 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Molecular Signatures of Cutaneous Dupilumab Response
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
- Trial name
- NCT05858619
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Asthma
Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants
Primary Objective: To evaluate the effects of SAR440340 with or without dupilumab, compared to placebo, on reducing the incidence of "loss of asthma control" (LOAC) events.
- Trial name
- NCT03387852
- Testing
- SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination
- Where
- 71 sites in United States, Argentina and 6 more
- Volunteers
- 296 people
- Sponsor
- Sanofi
Asthma
Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma
Primary Objective: To evaluate the efficacy of dupilumab in patients with persistent asthma Secondary Objectives: To evaluate the safety and tolerability of dupilumab To evaluate the effect of dupilumab on improving patient…
- Trial name
- NCT03782532
- Testing
- Dupilumab SAR231893, Asthma Controller Therapies (include prednisone/prednisolone), Asthma Reliever Therapies
- Where
- 67 sites in China, India
- Volunteers
- 486 people
- Sponsor
- Sanofi
Skin Inflammation, Allergic Contact Dermatitis
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
The purpose of this study is to answer: how do inflammation and anti-inflammatory skin therapies work in the skin? Inflammation is a protective response from the body's immune system to injury, disease, or irritation.
- Trial name
- NCT05535738
- Testing
- Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Wei-Che Ko
Asthma
Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma
The overall goal of this study is to understand biological responses related to dupilumab treatment among severe asthma patients. Not all asthma is the same, and characteristics of asthma vary from person to person.
- Trial name
- NCT05036733
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Michigan
Atopic Dermatitis
A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)
The primary objective of the study is to characterize the safety and pharmacokinetics (PK) of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis (AD) (for adolescents ≥12 to <18 years of age) or severe AD…
- Trial name
- NCT02407756
- Testing
- Dupilumab
- Where
- 26 sites in Canada, Czechia and 4 more
- Volunteers
- 78 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)
The purpose of this study was to assess the safety of Dupilumab administered concomitantly with topical corticosteroids (TCS) in patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01639040
- Testing
- Dupilumab, Topical Corticosteroid (TCS)
- Where
- 13 sites in Germany, Hungary and 1 more
- Volunteers
- 31 people
- Sponsor
- Regeneron Pharmaceuticals
Prurigo Nodularis (PN)
Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis
With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted…
- Trial name
- NCT07276425
- Testing
- Dupilumab
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- UMC Utrecht